2:15 PM
Sep 28, 2018
 |  BioCentury  |  Finance

Activating Akrevia

How preclinical POC on Akrevia’s tumor-activated therapies enabled its $30M series A

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners.

Akrevia, which emerged from stealth on Sept. 27, uses its Aklusion technology to design biological molecules such as antibodies, cytokines and chemokines that remain inactive until reaching the tumor microenvironment. Once these “Akluded” molecules reach the tumor microenvironment, they are activated by tumor-associated proteases.


Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >